#BETA DRUGS

ANNUAL REPORT FY21-22

MY TWO CENT
Second wave of COVID 19 impacted lives ,bussiness across the board.

We have also started to see inflation across economic in the world, interest rate increase and with ukrarian war conflict,supply chain constraints.

Even th world experienced chaos and disruption, we delivered our highest growth .

FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%

Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.
Beta Drugs’ commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals. The company continues to onboard new hospitals every month and is focused on expanding its branded product portfolio in the existing hospitals too. The company aims to become one of the top ten branded generic players in the oncology market in the near future.
The company is poised for strong growth for the next few years on the back of its strong R&D efforts to develop complex generics in the oncology space and continued expansion into new geographies.
Beta is focused on getting plant approvals and has many inspection/audits lined up for this year. It is continuing to file new product registrations across the ROW ( rest of world)countries and is poised to enter regulated markets soon.
Beta Drugs’ strong product pipeline of twenty-three products which are going off-patent in next five years includes NIBs, NDDS & PARP inhibitors. ( Chemotherapy) which will continue to support top line and margin expansion.
The company is also expanding its API capabilities by developing new products. It plans to file CEP( certificate of suitability) by Oct 2022. This backward integration helps the company to continuously expand its margins. The company has further got an allotment of 12 acres of land on 95years lease in a special area allocated for API & intermediates, where there is a single-window. This will help the company to take care of its future API capacity expansion.
The company is consolidating its institutional business and is continuously adding new logos every year. Beta has also entered into long term partnerships with three multinational pharma( very good sign) companies for its CMO business.
We believe that all our segments are slated to clock healthy growth with EBITDA margins in the range of 24% to 25%.
On behalf of the Board and management, I would like to thank our shareholders, customers

Subsidiary
#Beta UBK international ( Uzbekistan) 60 % shareholding
2.adley formulation 100% shareholding.
3. Adley lab 100% shareholding

Performance
Beta Uzbekistan
Engaged primarily in mfg oncology product approval were obtained on the lat quarter FY22 SALES couldn’t happen in 21-22 ( probably turn around story)

Adley formulation is primarily engaged in manufacturing & trading of oncology product turnover rs 5115 laks with profit rs 501 lakhs

Adley lab in mfg in oncology API ( very few companies had own api) turnover rs 3400 lakh with profitability rs 555.45 lakh

30 % salary hike ( imo negative)

Csr activities is done

Cashflows from operating activity almost double YOY ,( VERY GOOD SIGN) galle me bhi paisa a raha hai…

Disc
top 5 holding
Not sebi register.

(post deleted by author)

What is your view now?

Increased ticket prices are not a good sign for tourism or Thomas Cook as a larger share of customer spend goes away in tickets (leaving a less of spare cash) which otherwise could have presented a different opportunity for Tour operator to capture in their products.

Today stock came to 480 levels is this good price to entry?